Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives

There has been a rapid progress in developing genetically engineered T cells in recent years both in basic and clinical cancer studies. Chimeric antigen receptor (CAR)-T cells exert an immune response against various cancers, including the non-small-cell lung cancer (NSCLC). As novel agents of immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Jingjing, Mei, Quanhui, Chen, Lijun, Zhou, Jianying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907037/
https://www.ncbi.nlm.nih.gov/pubmed/33025047
http://dx.doi.org/10.1007/s00262-020-02735-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907037/
https://www.ncbi.nlm.nih.gov/pubmed/33025047
http://dx.doi.org/10.1007/s00262-020-02735-0

Ejemplares similares